Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Generation of New Bone Depends on WNT Stimulation of the mTORC1 Pathway

By BiotechDaily International staff writers
Posted on 18 Feb 2014
Image: As seen through a microscope, the leg bone of a normal mouse (left) makes considerably less new bone than a mouse that produces high levels of a signaling protein, WNT7B, that stimulates new bone growth (shown in pink on the right). The protein could become a target for new drugs to treat osteoporosis and other conditions related to bone loss (Photo courtesy of Washington University School of Medicine).
Image: As seen through a microscope, the leg bone of a normal mouse (left) makes considerably less new bone than a mouse that produces high levels of a signaling protein, WNT7B, that stimulates new bone growth (shown in pink on the right). The protein could become a target for new drugs to treat osteoporosis and other conditions related to bone loss (Photo courtesy of Washington University School of Medicine).
The WNT signaling protein WNT7B potently enhances formation of new bone through activation of mTORC1 (mammalian target of rapamycin) in a mouse osteoporosis model.

Previous studies have implicated WNT signaling in both embryonic and postnatal bone formation. However, the pertinent WNT ligands and their downstream signaling mechanisms are not well understood.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) used several lines of genetically engineered mice to examine the role of WNT signaling in bone formation.

The WNT gene family consists of structurally related genes that encode secreted signaling proteins. These proteins have been implicated in oncogenesis and in several developmental processes, including regulation of cell fate and patterning during embryogenesis. The WNT pathway involves a large number of proteins that can regulate the production of WNT signaling molecules, their interactions with receptors on target cells, and the physiological responses of target cells that result from the exposure of cells to the extracellular WNT ligands. Although the presence and strength of any given effect depends on the WNT ligand, cell type, and organism, some components of the signaling pathway are remarkably conserved in a wide variety of organisms.

Results published in the January 30, 2014, online edition of the journal PLOS Genetics revealed that WNT7B protein increased bone mass by stimulating formation of bone-building osteoblast cells while having no effect on the activity of bone-degrading osteoclasts. At the molecular level, it was seen that WNT7B exerted its effects through activation of the mTORC1 pathway. MTORC1 is a serine/threonine protein kinase of the phosphatidylinositol 3-kinase (PI3K) protein family that regulates cell growth, proliferation, motility, survival, protein synthesis, and transcription.

Genetic disruption of mTORC1 signaling prevented the WNT7B-induced formation of high-bone-mass phenotype mice.

“We have been looking for new ways to stimulate bone formation,” said senior author Dr. Fanxin Long, professor of medicine and developmental biology at the Washington University School of Medicine. “The tools we already have are very good at slowing the breakdown of bone, but we need better ways to stimulate new bone growth. By analyzing that information, mTOR can determine whether a cell should go into a mode to make lots of stuff, like proteins or, in this case, new bone. Bone formation is an energetically expensive process, so it makes sense that some regulator would tell a cell whether there is sufficient energy and material to manufacture new bone. It is still early, but our finding seems to point out that activating the mTOR pathway may be a good way to stimulate bone growth. This is a new twist because much of the current focus in mTOR-related drug development has been on compounds that inhibit the pathway to shut down cancer cells.”

Patients, such as organ transplant recipients, who have been treated with immunosuppressive drugs that inhibit the mTOR pathway often present with bone problems. “Many develop bone problems within a few months of receiving transplants because of the heavy doses of immunosuppressors they receive,” said Dr. Long. “Scientists have not looked carefully at how drugs used to prevent organ rejection can have a detrimental effect on bone, but our study would suggest that if those drugs inhibit mTOR, they could disrupt bone formation.”

Related Links:

Washington University School of Medicine



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.